EverHint Lens - Arcellx, Inc. (ACLX) - Yahoo Top Gainer Stock Analysis - February 23, 2026
Analysis Date: 2026-02-23
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Executive Summary
Arcellx, Inc. is currently trading at $113.81 (🟢 +77.52% today) with a market capitalization of $6.58B.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM).
Price & Valuation
Current Price: $113.81 (at 12:52 PM ET)
Current Volume: 20.2M (avg 1.1M)
Day Range: $113.80 - $114.26
52-Week Range: $47.86 - $114.26
P/E Ratio: N/A
DCF Valuation: Overvalued
- Intrinsic Value (Unlevered DCF): $46.20
- Current Price: $113.81
- Discount/Premium: -59.4%
Levered DCF: $33.11 (-70.9%)
DCF analysis suggests the stock may be trading at a 59.4% premium to its intrinsic value.
DCF values calculated as of 2026-02-23. Underlying assumptions are not disclosed by the data provider. Levered vs unlevered can diverge materially for highly levered companies.
Market Context
Healthcare Sector: 0.28761% | Sector P/E: 35.80
Major Indices:
- S&P 500: $6828.72 (🔴 -1.17%)
- NASDAQ Composite: $22587.41 (🔴 -1.30%)
- Dow Jones Industrial Average: $48806.41 (🔴 -1.65%)
Peer Comparison
Peer comparison (11 companies):
- ACLX - Arcellx, Inc. ($113.81, +77.5%) ← Current
- ARWR - Arrowhead Pharmaceuticals, Inc. ($62.91, -1.1%)
- PCVX - Vaxcyte, Inc. ($59.62, +1.9%)
- KYMR - Kymera Therapeutics, Inc. ($86.55, -1.0%)
- IMVT - Immunovant, Inc. ($26.91, +1.2%)
- PTGX - Protagonist Therapeutics, Inc. ($85.03, +2.7%)
- ALKS - Alkermes plc ($32.07, +0.5%)
- CRSP - CRISPR Therapeutics AG ($52.80, -1.2%)
- AKRO - Akero Therapeutics, Inc. ($54.65, 0.0%)
- NAMS - NewAmsterdam Pharma Company N.V. ($34.89, -1.9%)
- VKTX - Viking Therapeutics, Inc. ($33.95, +9.4%)
Financial Performance
Latest Quarter (2025-09-30):
- Revenue: $4.95M
- Net Income: $-55.78M
- EPS: $-0.99
- Revenue Growth (QoQ): -34.5%
Earnings Calendar
Next Earnings Report: 2026-02-26 (Before Market Open)
- EPS Estimate: $-1.01
Most Recent Report: 2025-11-05
- EPS: $-0.99 (Est: $-0.96) ✗ Miss
- Revenue: $0.00B
Historical Data: 21 earnings events tracked
Analyst Outlook
Analyst Price Target Consensus:
- Target: $108.00 (-5.1% upside)
- Range: $82.00 - $129.00
- Median: $115.00
Next Quarter Estimates (2026-12-30):
- Revenue: $32.50M
- EPS: $-1.00
Analyst Consensus
Overall Rating: Buy
Rating Distribution (103 total ratings):
- 🟢 Buy/Outperform: 103 (100.0%)
- ⚪ Hold/Neutral: 0 (0.0%)
- 🔴 Sell/Underperform: 0 (0.0%)
Recent Analyst Actions:
- Needham (2026-02-05): Maintained Buy
- HC Wainwright & Co. (2026-02-04): Maintained Buy
- Needham (2025-12-08): Maintained Buy
- Canaccord Genuity (2025-12-08): Maintained Buy
- Canaccord Genuity (2025-11-03): Maintained Buy
Consensus based on 103 analyst ratings from major financial institutions
Trading Signals
Our technical analysis identified 3 trading signal(s) in the last 60 days:
- 2026-02-19: Ema10 Ema30 - EMA10_x_EMA30_Sell @ $66.53
- 2026-02-05: Sma20 Sma50 - SMA20_x_SMA50_Buy @ $66.94
- 2026-02-04: Ema10 Sma50 - EMA10_x_SMA50_Buy @ $69.38
Insider Activity
Recent Transactions (Last 10):
- Buys: 1
- Sells: 9
Notable Transactions:
- 2026-02-19: Gilson Michelle - Sell (Sale, 2,879 shares @ $67.73)
- 2026-02-19: Gilson Michelle - Sell (Sale, 5,405 shares @ $68.57)
- 2026-02-19: Gilson Michelle - Sell (Sale, 100 shares @ $69.38)
News Sentiment Analysis
AI Analysis (based on 30 recent articles):
The dominant sentiment is highly positive driven by Gilead Sciences' $7.8 billion acquisition of Arcellx, sparking an 80% stock surge and validating its cancer therapy pipeline. Positive clinical data from iMMagine-1 and analyst 'Moderate Buy' ratings further bolster optimism. Minor concerns from shareholder investigations into deal fairness are overshadowed by the transformative deal.
Key Themes:
- Gilead acquisition
- Stock price surge
- Shareholder investigations
Sentiment: Positive (95% confidence)
Recent News
5 most recent articles covering ACLX:
- Shareholder Alert: The Ademi Firm investigates whether Arcellx Inc. is obtaining a Fair Price for its Public Shareholders (prnewswire.com, 2026-02-23) — Read more
- Shareholder Alert: The Ademi Firm investigates whether Arcellx Inc. is obtaining a Fair Price for its Public Shareholders (prnewswire.com, 2026-02-23) — Read more
- Why is Arcellx stock up 80% today? Gilead's $7.8B answer (invezz.com, 2026-02-23) — Read more
- Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion (reuters.com, 2026-02-23) — Read more
- ACLX Stock Alert: Halper Sadeh LLC is Investigating Whether Arcellx, Inc. is Obtaining a Fair Price for its Shareholders (businesswire.com, 2026-02-23) — Read more
Full news analysis based on 30 recent articles
Generated by Everhint Lens - Quantitative Stock Analysis
Last updated: 2026-02-23 09:52:28 AM PST
Disclaimer: This is not investment advice. Always do your own research before making investment decisions.